FDA Clears Bemotrizinol After 20-Year Gap in New Sunscreen Filters

Bemotrizinol provides photostable broad-spectrum absorption with peak efficacy at 4-6% concentration and minimal dermal penetration below FDA plasma thresholds. European post-marketing data from 1990 onward show no signals of contact allergy or endocrine activity at approved levels. U.S. approval followed reclassification under the 2020 CARES Act sunscreen monograph, which streamlined review of ingredients with existing international safety dossiers.

The 20-year delay stemmed from the 1999 sunscreen monograph's requirement for new drug applications rather than the EU's positive-list approach; this created a de facto barrier that left U.S. products reliant on older filters with narrower UVA coverage. Comparative studies in the British Journal of Dermatology (2022) demonstrated that formulations containing bemotrizinol plus avobenzone achieved 30-40% higher UVA-PF scores than U.S. market leaders at equivalent SPF.

Products are projected to reach shelves by late 2026, with formulators citing improved aesthetics and reduced white cast versus mineral-only options. Remaining questions center on real-world adherence gains and whether additional filters (ecamsule, drometrizole trisiloxane) will follow under the same pathway within 36 months.